Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACAD – Research Report) and Enhabit, Inc (EHAB – Research Report).
ACADIA Pharmaceuticals (ACAD)
In a report issued on March 6, Uy Ear from Mizuho Securities maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $39.00. The company’s shares closed last Friday at $23.44.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.82, implying a 45.5% upside from current levels. In a report issued on February 27, RBC Capital also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Enhabit, Inc (EHAB)
In a report issued on March 6, Whit Mayo from Leerink Partners reiterated a Sell rating on Enhabit, Inc. The company’s shares closed last Friday at $10.34.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Enhabit, Inc with a $10.38 average price target, which is a 7.3% upside from current levels. In a report issued on March 7, Bank of America Securities also maintained a Sell rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- Acadia Pharmaceuticals should be bought on weakness, says Mizuho
- Australian Stocks: Neuren’s (NEU) Daybue Sales Fail to Impress, Shares Plunge
- Acadia Pharmaceuticals provides FY24 product sales guidance
- Acadia Pharmaceuticals reports Q4 EPS 28c, consensus 30c
- ACADIA Pharmaceuticals Inc. (ACAD) Q4 Earnings Cheat Sheet
